Searchable abstracts of presentations at key conferences in endocrinology

ea0022p661 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

SSTR5 ligand binding domain immunohistological detection in pituitary adenomas using Y-SSTR5 a new mouse monoclonal antibody

Rossi Valentina , Staibano Stefania , Del Basso De Caro Laura , Bellastella Giuseppe , Ilardi Gennaro , Cavallo Luigi , Colao Annamaria , Agostino Sinisi Antonio

Polyclonal antibodies against somatostatin receptors (SSTRs) available up to now recognizing intracellular sites of receptors and their recycling products do not detect bioactive ligand binding domains (LBDs) and are of limited performance in paraffin-embedded tissues. Aim of this study was to evaluate by immunohistochemistry the expression of SSTR5 on an archival series of pituitary tumors using a new MoAbs against the SST-binding domain (Y-SSTR5).Metho...

ea0049ep927 | Pituitary - Basic | ECE2017

Ketoconazole induces inhibition of cell viability and apoptosis in an ACTH-secreting tumour cell line model

Patalano Roberta , Pivonello Claudia , Solari Domenico , Vitulli Francesca , Iacuaniello Davide , Leo Monica De , Negri Mariarosaria , Provvisiero Donatella Paola , Cavallo Luigi Maria , Cappabianca Paolo , Colpo Annamaria , Pivonello Rosario

Chronic cortisol excess as a consequence of ACTH overproduction from a pituitary tumour is responsible for the development of Cushing’s disease (CD). The first-line treatment for CD is pituitary surgery, but medical treatment is an alternative second-line approach to control cortisol excess. Among pharmacological agents, the adrenal-blocking drug ketoconazole (KT), is able to control cortisol excess in the majority of patients with CD. During KT treatment, the adrenal blo...